Risperidone

Evidence Level: L5

Predicted Indications: 4

Risperidone

Pharmacist Assessment Report

Risperidone: Gaze palsy, familial horizontal, with progressive scoliosis

One-Sentence Summary

Risperidone is an atypical antipsychotic marketed in India as oral tablets. The TxGNN model predicts it may be effective for gaze palsy, familial horizontal, with progressive scoliosis, but no clinical trials and no publications currently support this prediction.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Gaze palsy, familial horizontal, with progressive scoliosis
TxGNN Prediction Score	0.9976
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Risperidone is generally understood to act through dopamine D2 and serotonin 5-HT2A receptor antagonism.

The predicted disease is a rare inherited disorder of horizontal eye movement with progressive scoliosis, linked to the ROBO3 gene. It has no plausible dopaminergic or serotonergic target that risperidone would act on, and no mechanistic link has been established. The high score is therefore best treated as a statistical output of the model rather than a biologically grounded signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Risperidone is currently marketed in India. All 20 records in the compiled data are valid single-ingredient licences, and the list may be partial. The licence records carry no indication text. The main authorizations are:

Authorization Number	Product Name	Dosage Form	Manufacturer
186077	Respidon 3 Tablet	Strip of 10 tablets	Torrent Pharmaceuticals Ltd
189472	Repadone 4mg Tablet	Strip of 10 tablets	Shine Pharmaceuticals Ltd
184310	Risdone-Plus Tablet	Strip of 10 tablets	Intas Pharmaceuticals Ltd
185469	Risnia MD 4 Tablet	Strip of 10 mouth-dissolving tablets	Cipla Ltd
249775	Zisper 2mg Tablet MD	Strip of 10 mouth-dissolving tablets	Torrent Pharmaceuticals Ltd

Safety Considerations

Drug Interactions: 362 interactions are recorded. Major-level interactions include bupropion and morphine. Many moderate-level interactions are also listed, including acarbose, metformin, famotidine, epinephrine, hydrocortisone, amphotericin B, atropine and loperamide.

Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no clinical trials, no publications and no plausible mechanistic link. Evidence level is L5 (model prediction only).

To proceed, the following is needed:

Any biological rationale linking risperidone’s receptor pharmacology to ROBO3-related horizontal gaze palsy
Mechanism of action data and package insert safety information
Preclinical or clinical studies directly addressing this disease

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.